- Home
- MDLZ vs BMY Comparison
MDLZ vs BMY Comparison
Compare MDLZ & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDLZ
- BMY
- Stock Information
- Founded
- MDLZ 2000
- BMY 1887
- Country
- MDLZ United States
- BMY United States
- Employees
- MDLZ N/A
- BMY N/A
- Industry
- MDLZ Packaged Foods
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- MDLZ Consumer Staples
- BMY Health Care
- Exchange
- MDLZ Nasdaq
- BMY Nasdaq
- Market Cap
- MDLZ 99.1B
- BMY 103.2B
- IPO Year
- MDLZ N/A
- BMY N/A
- Fundamental
- Price
- MDLZ $71.23
- BMY $52.78
- Analyst Decision
- MDLZ Strong Buy
- BMY Hold
- Analyst Count
- MDLZ 18
- BMY 15
- Target Price
- MDLZ $79.56
- BMY $53.36
- AVG Volume (30 Days)
- MDLZ 4.8M
- BMY 11.1M
- Earning Date
- MDLZ 10-29-2024
- BMY 10-31-2024
- Dividend Yield
- MDLZ 2.64%
- BMY 4.54%
- EPS Growth
- MDLZ N/A
- BMY N/A
- EPS
- MDLZ 2.91
- BMY N/A
- Revenue
- MDLZ $35,976,000,000.00
- BMY $46,509,000,000.00
- Revenue This Year
- MDLZ $3.61
- BMY $5.03
- Revenue Next Year
- MDLZ $4.61
- BMY N/A
- P/E Ratio
- MDLZ $24.53
- BMY N/A
- Revenue Growth
- MDLZ 5.41
- BMY 2.93
- 52 Week Low
- MDLZ $64.16
- BMY $39.35
- 52 Week High
- MDLZ $77.20
- BMY $56.77
- Technical
- Relative Strength Index (RSI)
- MDLZ 40.89
- BMY 56.59
- Support Level
- MDLZ $69.93
- BMY $51.31
- Resistance Level
- MDLZ $71.82
- BMY $53.42
- Average True Range (ATR)
- MDLZ 0.98
- BMY 1.09
- MACD
- MDLZ -0.11
- BMY -0.17
- Stochastic Oscillator
- MDLZ 27.80
- BMY 47.11
About MDLZ Mondelez International Inc.
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack enclave with a presence in the biscuit (49% of sales), chocolate (30%), gum/candy (12%), beverage (3%), and cheese and grocery (6%) aisles, as of the end of fiscal 2023. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, and Cadbury, among others. The firm derives around one third of revenue from developing markets, just more than one third from Europe, and the remainder from North America.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.